Abstract
Background Association of endovascular therapy (EVT) with clinical outcomes beyond 24 hours remains unclear. We conducted a meta-analysis to answer this question.
Methods We searched for eligible studies in PubMed from inception until June 2023. The outcomes included functional independence, as assessed with 90-day modified Rankin Scale (mRS) scores (0-2), thrombolysis in cerebral infarction (TICI) scores (2b-3 or 3), symptomatic intracranial hemorrhage (sICH), and 90-day mortality. Risk ratio (RR) and 95% confidence interval (CI) were pooled.
Results We finally included 13 studies in our meta-analysis (number of patients treated with EVT beyond 24 h=866). For single arm analysis, the pooled estimates of functional independence (mRS 0-2), sICH, and mortality were 0.342 (95% CI = 0.275 -0.410, P < 0.001), 0.062 (95% CI = 0.045 -0.078, P < 0.001), and 0.232 (95% CI = 0.164 -0.301, P < 0.001); respectively with successful reperfusion (TICI 2b-3) of 0.837 (95% CI = 0.812 -0.861, P < 0.001). Comparing EVT with medical management, the pooled analysis showed that EVT had a statistically significant advantage over medical management (RR = 2.62, 95% CI [1.38, 4.96], P = 0.003). However, our analysis showed a higher incidence of sICH in EVT group (RR = 3.58, 95% CI [1.53, 8.37], P = 0.003). When we pooled studies comparing EVT beyond 24 h with EVT within 6–24 h, the findings showed no statistically significant difference for functional independence, sICH, and 90-d Mortality.
Conclusion EVT is associated with better clinical outcomes than medical management beyond 24 hours. These results are iconoclastic enhancing a new paradigm in which a contemporary restriction to specific time window to treat patients rather than their own clinical and imaging characteristics seems to be anecdotal. Prospective studies are needed to confirm the best eligible patients for EVT in this newly proposed window extension.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
